The effect of magnesium supplementation on hyperoxaluria and calcium oxalate supersaturation in kidney stone patients

The effect of oral magnesium citrate and magnesium oxide supplementation on hyperoxaluria and calcium oxalate supersaturation in kidney stone patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191026045244N1

Enrollment

Registered

2019-12-03

Start date

2016-06-21

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney stone. Calculus of kidney

Interventions

Intervention 1: Intervention group: Magnesium Oxide. Intervention 2: Intervention group: Magnesium Citrate. Intervention 3: Control group: Placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Hyperoxaluria (24-hour urine oxalate over 40 and less than 80 mg) Patients with a history of kidney stone referred to kidney stone prevention clinic of Labbafinejad at least 20 days since the last treatment they have at least 3 months since following general dietary advice on recurrence prevention (drinking advice, high oxalate food restriction, animal protein restriction, fruit and vegetable intake encouragement, salt restriction and fat intake modification) willingness to cooperate in the study

Exclusion criteria

Exclusion criteria: Primary or enteric hyperoxaluria (urine oxalate>80 mg/24h) Taking any drugs which affects calcium metabolism, including thiazides, potassium citrate, calcium supplement, magnesium supplement and Laxatives Taking any drugs which affects oxalate metabolism or calcium oxalate supersaturation, including vitamin B6 History of diabetes mellitus, hepatic failure, thyroid or parathyroid diseases, chronic kiodney disease (CKD), Urinary tract infection (UTI), chronic diarrhea or immunologic diseases Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
24 hour urine oxalate. Timepoint: Before the intervention, 8 weeks after intervention. Method of measurement: Enzymatic method.;Calcium oxalate supersaturation. Timepoint: Before the intervention, 8 weeks after intervention. Method of measurement: Calculation by LITHORISK software.	—

Secondary

Measure	Time frame
24 hour urine magnesium. Timepoint: Before the intervention, 8 weeks after intervention. Method of measurement: Chemical Method - Calorimetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Taheri

Shahid Beheshti University of Medical Sciences

taheri233@yahoo.com+98 0212256722

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026